Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 12/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 12/20 | 0.54 |
| ▸ | WNT1 | P04628 | 7/20 | 0.54 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 3/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10165990 | 0.90 | GSK3B (0.52) | GSK3BDYRK1AWNT1USP30ROCK2 | |
| SCHEMBL560197 | 0.87 | ABL1 (0.58) | GSK3BDYRK1AWNT1USP30ROCK2 | |
| SCHEMBL23923853 | 0.84 | ABL1 (0.48) | GSK3BDYRK1AWNT1ROCK2ABL1 | |
| SCHEMBL23923854 | 0.84 | ABL1 (0.48) | GSK3BDYRK1AWNT1ROCK2ABL1 | |
| SCHEMBL19515815 | 0.79 | GSK3B (0.73) | GSK3BDYRK1AWNT1USP30ABL1 | |
| SCHEMBL19516111 | 0.78 | DYRK1A (0.71) | GSK3BDYRK1AWNT1USP30ABL1 | |
| SCHEMBL17632071 | 0.77 | DYRK1A (0.63) | GSK3BDYRK1AWNT1USP30 | |
| SCHEMBL19516204 | 0.76 | GSK3B (0.70) | GSK3BDYRK1AWNT1USP30ABL1 | |
| SCHEMBL19516327 | 0.76 | GSK3B (0.67) | GSK3BDYRK1AWNT1USP30ABL1 | |
| SCHEMBL559169 | 0.75 | DYRK1A (0.73) | GSK3BDYRK1AWNT1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | GSK3B 685/4885DYRK1A 1064/4885WNT1 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.